Cisplatin or Doxorubicin Reduces Cell Viability via the PTPIVA3-JAK2-STAT3 Cascade in Hepatocellular Carcinoma

References

• Zhu RX, Seto WK, Lai CL, et al. Epidemiology of hepatocellular carcinoma in the Asia-pacific region. Gut Liver. 2016;10:332–339.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Worns MA, Weinmann A, Schuchmann M, et al. Systemic therapies in hepatocellular carcinoma. Digestive Dis. 2009;27:175–188.
   PubMed Web of Science ®Google Scholar
• Yau T, Chan P, Epstein R, et al. Evolution of systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol. 2008;14:6437–6441.
   PubMed Web of Science ®Google Scholar
• Yau T, Chan P, Epstein R, et al. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int. 2009;29:10–17.
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.
   PubMed Web of Science ®Google Scholar
• Ho CM, Hu RH, Lee PH, et al. Long-term survival in patients with t2 hepatocellular carcinoma after primary curative resection can be further stratified by tumor size. Medicine. 2014;93:e203.
   Web of Science ®Google Scholar
• European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
   PubMed Web of Science ®Google Scholar
• Cao H, Phan H, Yang LX. Improved chemotherapy for hepatocellular carcinoma. Anticancer Res. 2012;32:1379–1386.
   PubMed Web of Science ®Google Scholar
• Park KW, Park JW, Choi JI, et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis b virus-endemic area. J Gastroenterol Hepatol. 2008;23:467–473.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9:166–180.
   PubMed Web of Science ®Google Scholar
• Basak S, Jacobs SB, Krieg AJ, et al. The metastasis-associated gene prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell. 2008;30:303–314.
   PubMed Web of Science ®Google Scholar
• Cox J, Weinman S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepatic Oncol. 2016;3:57–59.
   PubMed Web of Science ®Google Scholar
• Lohitesh K, Chowdhury R, Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int. 2018;18:44.
   PubMed Web of Science ®Google Scholar
• Bessette DC, Wong PC, Pallen CJ. Prl-3: a metastasis-associated phosphatase in search of a function. Cells Tissues Organs. 2007;185:232–236.
   Web of Science ®Google Scholar
• Hardy S, Kostantin E, Hatzihristidis T, et al. Physiological and oncogenic roles of the prl phosphatases. FEBS J. 2018;285:3886–3908.
   PubMed Web of Science ®Google Scholar
• Al-Aidaroos AQ, Zeng Q. Prl-3 phosphatase and cancer metastasis. J Cell Biochem. 2010;111:1087–1098.
   Web of Science ®Google Scholar
• Laurent C, Valet F, Planque N, et al. High ptp4a3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res. 2011;71:666–674.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Dong JM, Guo K, et al. Prl-3 and prl-1 promote cell migration, invasion, and metastasis. Cancer Res. 2003;63:2716–2722.
   PubMed Web of Science ®Google Scholar
• Zhou J, Chong PS, Lu X, et al. Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia. Exp Hematol. 2014;42(1041–1052):e1041–e1042.
   Google Scholar
• Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, et al. Interleukin-6-dependent gene expression profiles in multiple myeloma ina-6 cells reveal a bcl-2 family-independent survival pathway closely associated with stat3 activation. Blood. 2004;103:242–251.
   Web of Science ®Google Scholar
• Chong PSY, Chng WJ, de Mel S. Stat3: a promising therapeutic target in multiple myeloma. Cancers. 2019;11:731.
   Web of Science ®Google Scholar
• Chong PSY, Zhou J, Lim JSL, et al. Il6 promotes a stat3-prl3 feedforward loop via shp2 repression in multiple myeloma. Cancer Res. 2019;79:4679–4688.
   Web of Science ®Google Scholar
• Zhou J, Bi C, Chng WJ, et al. Prl-3, a metastasis associated tyrosine phosphatase, is involved in flt3-itd signaling and implicated in anti-aml therapy. PLoS One. 2011;6:e19798.
   PubMed Web of Science ®Google Scholar
• Wang L, Liu J, Zhong Z, et al. Ptp4a3 is a target for inhibition of cell proliferatin, migration and invasion through akt/mtor signaling pathway in glioblastoma under the regulation of mir-137. Brain Res. 2016;1646:441–450.
   Web of Science ®Google Scholar
• Mayinuer A, Yasen M, Mogushi K, et al. Upregulation of protein tyrosine phosphatase type iva member 3 (ptp4a3/prl-3) is associated with tumor differentiation and a poor prognosis in human hepatocellular carcinoma. Ann Surg Oncol. 2013;20:305–317.
   Web of Science ®Google Scholar
• Vandsemb EN, Bertilsson H, Abdollahi P, et al. Phosphatase of regenerating liver 3 (prl-3) is overexpressed in human prostate cancer tissue and promotes growth and migration. J Transl Med. 2016;14:71.
   PubMed Web of Science ®Google Scholar
• Chen CY, Chung IH, Tsai MM, et al. Thyroid hormone enhanced human hepatoma cell motility involves brain-specific serine protease 4 activation via erk signaling. Mol Cancer. 2014;13:162.
   PubMed Web of Science ®Google Scholar
• Chow EK, Fan LL, Chen X, et al. Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells. Hepatology. 2012;56:1331–1341.
   Web of Science ®Google Scholar
• Ma S, Lee TK, Zheng BJ, et al. Cd133+ HCC cancer stem cells confer chemoresistance by preferential expression of the akt/pkb survival pathway. Oncogene. 2008;27:1749–1758.
   PubMed Web of Science ®Google Scholar
• Roessler S, Jia HL, Budhu A, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70:10202–10212.
   PubMed Web of Science ®Google Scholar
• Ng KT, Lo CM, Guo DY, et al. Identification of transmembrane protein 98 as a novel chemoresistance-conferring gene in hepatocellular carcinoma. Mol Cancer Ther. 2014;13:1285–1297.
   Web of Science ®Google Scholar
• Burridge K, Sastry SK, Sallee JL. Regulation of cell adhesion by protein-tyrosine phosphatases. I. Cell-matrix adhesion. J Biol Chem. 2006;281:15593–15596.
   PubMed Web of Science ®Google Scholar
• Werner SR, Lee PA, DeCamp MW, et al. Enhanced cell cycle progression and down regulation of p21(cip1/waf1) by prl tyrosine phosphatases. Cancer Lett. 2003;202:201–211.
   PubMed Web of Science ®Google Scholar
• den Hollander P, Rawls K, Tsimelzon A, et al. Phosphatase ptp4a3 promotes triple-negative breast cancer growth and predicts poor patient survival. Cancer Res. 2016;76:1942–1953.
   PubMed Web of Science ®Google Scholar
• Zhou J, Cheong LL, Liu SC, et al. The pro-metastasis tyrosine phosphatase, prl-3 (ptp4a3), is a novel mediator of oncogenic function of bcr-abl in human chronic myeloid leukemia. Mol Cancer. 2012;11:72.
   PubMed Web of Science ®Google Scholar
• Liang F, Liang J, Wang WQ, et al. Prl3 promotes cell invasion and proliferation by down-regulation of csk leading to src activation. J Biol Chem. 2007;282:5413–5419.
   PubMed Web of Science ®Google Scholar
• Mertens C, Darnell JE. Snapshot: jak-stat signaling. Cell. 2007;131:612.
   PubMed Web of Science ®Google Scholar
• Johnson DE, O’Keefe RA, Grandis JR. Targeting the il-6/jak/stat3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234–248.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Si X, Horstmann H, et al. Prenylation-dependent association of protein-tyrosine phosphatases prl-1, −2, and −3 with the plasma membrane and the early endosome. J Biol Chem. 2000;275:21444–21452.
   PubMed Web of Science ®Google Scholar
• Fiordalisi JJ, Keller PJ, Cox AD. Prl tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res. 2006;66:3153–3161.
   PubMed Web of Science ®Google Scholar
• Wang H, Quah SY, Dong JM, et al. Prl-3 down-regulates PTEN expression and signals through pi3k to promote epithelial-mesenchymal transition. Cancer Res. 2007;67:2922–2926.
   PubMed Web of Science ®Google Scholar
• Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006;6:307–320.
   PubMed Web of Science ®Google Scholar
• Bollu LR, Mazumdar A, Savage MI, et al. Molecular pathways: targeting protein tyrosine phosphatases in cancer. Clin Cancer Res. 2017;23:2136–2142.
   Web of Science ®Google Scholar
• Fiordalisi JJ, Dewar BJ, Graves LM, et al. Src-mediated phosphorylation of the tyrosine phosphatase prl-3 is required for prl-3 promotion of rho activation, motility and invasion. PLoS One. 2013;8:e64309.
   PubMed Web of Science ®Google Scholar
• Walls CD, Iliuk A, Bai Y, et al. Phosphatase of regenerating liver 3 (prl3) provokes a tyrosine phosphoproteome to drive prometastatic signal transduction. Mol Cell Proteomics. 2013;12:3759–3777.
   PubMed Web of Science ®Google Scholar
• Hu T, Li C. Convergence between wnt-beta-catenin and egfr signaling in cancer. Mol Cancer. 2010;9:236.
   PubMed Web of Science ®Google Scholar
• Guo K, Li J, Tang JP, et al. Catalytic domain of prl-3 plays an essential role in tumor metastasis: formation of prl-3 tumors inside the blood vessels. Cancer Biol Ther. 2004;3:945–951.
   PubMed Web of Science ®Google Scholar
• Ahn JH, Kim SJ, Park WS, et al. Synthesis and biological evaluation of rhodanine derivatives as prl-3 inhibitors. Bioorg Med Chem Lett. 2006;16:2996–2999.
   PubMed Web of Science ®Google Scholar
• Beekman R, Valkhof M, Erkeland SJ, et al. Retroviral integration mutagenesis in mice and comparative analysis in human aml identify reduced ptp4a3 expression as a prognostic indicator. PLoS One. 2011;6:e26537.
   Web of Science ®Google Scholar
• Souissi I, Ladam P, Cognet JA, et al. A stat3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between stat1 and stat3 and induces death in a human colon carcinoma cell line. Mol Cancer. 2012;11:12.
   Web of Science ®Google Scholar
• Al Zaid Siddiquee K, Turkson J. Stat3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008;18:254–267.
   PubMed Web of Science ®Google Scholar
• Beldi-Ferchiou A, Skouri N, Ben Ali C, et al. Abnormal repression of shp-1, shp-2 and socs-1 transcription sustains the activation of the jak/stat3 pathway and the progression of the disease in multiple myeloma. PLoS One. 2017;12:e0174835.
   PubMed Web of Science ®Google Scholar
• Galm O, Yoshikawa H, Esteller M, et al. Socs-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 2003;101:2784–2788.
   PubMed Web of Science ®Google Scholar